Table 4 The risk of death for lung cancer patients, Cox regression for patients diagnosed with lung cancer in 2018–2022 in Norway
From: Distribution and characteristics of malignant tumours by lung lobe
Univariable | Multivariable | |
|---|---|---|
Hazard Ratio (95%CI) | Hazard Ratio (95%CI) | |
Lobe | ||
RUL | 1.00 | 1.00 |
LUL | 1.04 (0.98–1.10) | 1.01 (0.95–1.07) |
RML | 0.97 (0.87–1.09) | 1.09 (0.97–1.22) |
RLL | 0.99 (0.92–1.05) | 0.99 (0.92–1.06) |
LLL | 0.99 (0.92–1.07) | 1.02 (0.95–1.10) |
p-value | 0.55 | 0.56 |
Age | 1.03 (1.03–1.03) | 1.03 (1.02–1.03) |
p-value | 0.00 | 0.00 |
Sex | ||
Female | 1.00 | 1.00 |
Male | 1.28 (1.23–1.34) | 1.21 (1.16–1.27) |
p-value | 0.00 | 0.00 |
cTNM | ||
I | 1.00 | 1.00 |
II | 1.94 (1.73–2.18) | 1.48 (1.31–1.68) |
III | 3.72 (3.41–4.05) | 1.98 (1.79–2.19) |
IV | 8.74 (8.11–9.42) | 3.46 (3.13–3.81) |
p-value | 0.00 | 0.00 |
Histology | ||
AC | 1.00 | 1.00 |
SCC | 1.24 (1.17–1.31) | 1.40 (1.32–1.49) |
NSCLC- NOS | 2.05 (1.89–2.23) | 1.44 (1.33–1.57) |
Large-cell | 1.50 (1.24–1.80) | 1.54 (1.28–1.86) |
SCLC | 2.46 (2.32–2.60) | 1.62 (1.52–1.71) |
Carcinoid | 0.14 (0.10–0.20) | 0.35 (0.25–0.49) |
Other | 1.13 (0.96–1.32) | 1.45 (1.23–1.70) |
p-value | 0.00 | 0.00 |
EGFR | ||
Not tested | 1.50 (1.33–1.69) | |
Positive | 1.00 | |
Negative | 0.93 (0.55–1.02) | |
p-value | 0.00 | |
First treatment | ||
Resected | 1.00 | 1.00 |
SBRT | 2.07 (1.82–2.35) | 1.74 (1.52–1.98) |
Cur rad | 3.73 (3.34–4.17) | 1.95 (1.73–2.20) |
Pall rad | 11.05 (10.05–12.15) | 4.14 (3.70–4.63) |
Unknown rad | 8.51 (6.85–10.57) | 2.94 (2.34–3.69) |
No treatment reported | 12.50 (11.42–13.69) | 4.97 (4.47–5.54) |
p-value | 0.00 | 0.00 |